Newly Discovered Biomarker May Help Personalize Colorectal Cancer Treatment
Researchers might be on to a new biomarker for patients with colorectal cancer, says Martin D. Berger, M.D., oncologist at the University of Southern California.
Researchers might be on to a new biomarker for patients with colorectal cancer, says Martin D. Berger, M.D., oncologist at the University of Southern California.
In a phase 3 trial conducted in Europe, 300 patients with metastatic colorectal cancer were assigned a treatment regimen of FOLFIRI plus bevacizumab, while 300 other patients — who had the same staging and type of disease – were given FOLFIRI plus cetuximab. The patients who had the genetic mutation to transport vitamin C had better outcomes and survival on the FOLFIRI plus bevacizumab regimen, while survival for patients with and without this mutation was the same for the group given FOLFIRI and cetuximab.
Findings like these, paired with further investigation, may lead to better personalizing treatment for patients with metastatic colorectal cancer.
The Sport of Cancer: How One Survivor Linked Ironman Training and Colorectal Cancer
February 16th 2023Teri Griege completed an Ironman triathlon in 2009, and less than a month later received a stage 4 colorectal cancer diagnosis. In this episode of Cancer Horizons, she shared her story.
Listen
‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC
January 27th 2022In this episode of the “Cancer Horizons” podcast, a woman living with colorectal cancer who was diagnosed 14 years ago at age 29 discusses what it was like to be the youngest person in the treatment room, and how she found another community of young survivors.
Listen
